Core Viewpoint - Haofan Bio experienced a 5.23% increase in stock price, reaching 58.20 CNY per share, with a trading volume of 116 million CNY and a turnover rate of 4.82%, resulting in a total market capitalization of 6.286 billion CNY [1] Company Overview - Suzhou Haofan Bio Co., Ltd. is located at Changting Road 1, Suzhou High-tech Zone, Jiangsu Province, and was established on December 2, 2003. The company went public on July 12, 2023. Its main business involves the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] Shareholder Information - Among the top ten circulating shareholders of Haofan Bio, a fund under Huatai PineBridge holds a position. The Huatai Medical and Health Mixed Fund (470006) entered the top ten circulating shareholders in the second quarter, holding 602,500 shares, which accounts for 1.5% of the circulating shares. It is estimated that the fund has earned approximately 1.7411 million CNY in floating profit today [2] - The Huatai Medical and Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.358 billion CNY. Year-to-date returns stand at 35.59%, ranking 1703 out of 8254 in its category; the one-year return is 41.87%, ranking 3403 out of 8037; and since inception, the return is 171.31% [2] - The fund manager of Huatai Medical and Health Mixed Fund (470006) is Zheng Lei, who has a cumulative tenure of 10 years and 262 days. The total asset scale under his management is 7.072 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -21.99% [2]

Group 1 - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [2] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [3] - The company plans to repurchase its A-shares using its own funds, with a total repurchase amount between 30 million and 60 million RMB, and a maximum repurchase price of 60.00 RMB per share [3] Group 2 - As of February 5, 2025, the company has repurchased a total of 1,028,148 shares, accounting for 0.95% of the total share capital, with a total transaction amount of approximately 41.99 million RMB [4]

Core Viewpoint - Haofan Bio announced the approval of a financing guarantee for its wholly-owned subsidiaries, totaling up to 600 million yuan, to support project construction and daily operations [1] Group 1 - The company will provide a joint liability guarantee of up to 500 million yuan for its subsidiary Huai'an Haofan Biopharmaceutical Co., Ltd. [1] - The company will also provide a joint liability guarantee of up to 100 million yuan for Suzhou Haofan Import and Export Co., Ltd. [1] - The board and supervisory meetings were held on August 27, 2025, to approve the guarantee proposal [1]

Core Viewpoint - Haofan Bio (301393.SZ) reported a revenue of 270 million yuan for the first half of 2025, reflecting a year-on-year growth of 20.10% [1] - The net profit attributable to shareholders of the listed company was 75.8848 million yuan, representing a year-on-year increase of 15.31% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 62.0004 million yuan, showing a year-on-year growth of 4.58% [1] - The basic earnings per share stood at 0.71 yuan [1] Financial Performance - Revenue for the first half of 2025 reached 270 million yuan, up 20.10% compared to the previous year [1] - Net profit attributable to shareholders increased to 75.8848 million yuan, a rise of 15.31% year-on-year [1] - Net profit after deducting non-recurring items was 62.0004 million yuan, marking a 4.58% increase from the previous year [1] - Basic earnings per share were reported at 0.71 yuan [1]

Group 1 - The core viewpoint of the article is that Haofan Bio (301393.SZ) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong business performance [1] Group 2 - The company achieved an operating income of 270 million yuan, representing a year-on-year growth of 20.10% [1] - The net profit attributable to shareholders of the listed company was 75.8848 million yuan, showing a year-on-year increase of 15.31% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 62.0004 million yuan, with a year-on-year growth of 4.58% [1] - The basic earnings per share were reported at 0.71 yuan [1]

Group 1 - The company Haofan Bio announced the convening of its fourth board meeting on August 27, 2025, to review the 2025 semi-annual report and summary [1] - For the year 2024, Haofan Bio's revenue composition is entirely from the manufacturing of chemical raw materials and chemical products, accounting for 100.0% [1] - As of the report date, Haofan Bio has a market capitalization of 6 billion yuan [1]

证券代码：301393 证券简称：昊帆生物 公告编号：2025-047 苏州昊帆生物股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 苏州昊帆生物股份有限公司（以下简称"公司"或"昊帆生物"）本次担保 额度中的被担保人包含资产负债率超过 70%的子公司。前述担保均是合并报表范 围内公司及全资子公司之间的担保，担保风险处于公司可控制范围之内，敬请广 大投资者注意投资风险。 一、担保情况概述 公司于 2025 年 8 月 27 日召开第四届董事会第十二次会议、第四届监事会第 十次会议，审议通过了《关于为全资子公司提供担保的议案》。同意公司为全资 子公司提供总金额不超过 60,000.00 万元的融资担保，具体如下： 为满足项目建设需要，公司拟为全资子公司淮安昊帆生物医药有限公司（以 下简称"淮安昊帆"）向交通银行股份有限公司申请贷款等融资业务提供不超过 人民币 50,000.00 万元（含本数）的连带责任担保；为满足日常经营需要，公司 拟为全资子公司苏州昊帆进出口有限公司（以下简称"昊帆进出口"）向宁波银 行 ...

| 编制单位：苏州昊帆生物股份有限公司 | | | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关联关 | 上市公司核算的会 | 2025年期初占用 | 2025年半年度占用累计 | | 2025年半年度往来资金的 | 2025年半年度偿还累 | 2025年6月30日占用 资金余额 | | 占用形成原因 | 占用性质 | | | | 系 | 计科目 | 资金余额 | 发生金额（不含利息） | | 利息（如有） | 计发生金额 | | | | | | 控股股东、实际控制人及其附属 企业 | - | - | - | - | | - | - | - | | - | - | - | | 小 计 | - | - | - | - | | - | - | - | | - | - | - | | 前控股股东、实际控制人及其附 属企业 | - | - | - | - | | - | - | - | ...

证券代码：301393 证券简称：昊帆生物 公告编号：2025-046 苏州昊帆生物股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公司自律监管 指南第 2 号——公告格式》等规定，苏州昊帆生物股份有限公司（以下简称"昊 帆生物"、"公司"或"本公司"）董事会编制了 2025 年半年度（以下简称"报 告期"或"本报告期"）募集资金存放与实际使用情况专项报告如下： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意苏州昊帆生物股份有限公司首次公开 发行股票注册的批复》（证监许可[2023]806 号）同意注册，本公司首次公开发 行 2,700.00 万股人民币普通股（A 股），每股面值为人民币 1.00 元，每股发行 价格为 67.68 元，实际募集资金总额为人民币 1,827,360,000.00 元，扣除发 ...

证券代码：301393 证券简称：昊帆生物 公告编号：2025-045 苏州昊帆生物股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 苏州昊帆生物股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日在公 司以现场方式召开第四届监事会第十次会议。会议通知于 2025 年 8 月 16 日以专 人送达及电话等方式发出。 （一）审议并通过《关于公司 2025 年半年度报告及摘要的议案》 经审议，监事会认为：董事会编制和审核公司 2025 年半年度报告及其摘要 的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 与会监事以记名投票表决方式，审议并通过了如下议案： 表决结果：3 名监事同意，占全体监事人数的 100%；0 名弃权；0 名反对。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）上披露的《2025 年半年度报告》和《2025 年半年度报告摘要》。 （二）审议并通过《关于 ...